Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has completed the first stage of its collaboration with Australian biotechnology company, Phylogica, for the discovery of novel peptide-based vaccines.
Subscribe to our email newsletter
Both the companies entered into the collaboration in December 2010 under which Phylogica has identified various peptides from its Phylomer libraries that will be further evaluated for their potential as candidate antigens for a vaccine.
Phylogica CEO Paul Watt said the company has identified multiple novel Phylomers that meet the criteria required for further evaluation by Pfizer.
"This provides additional support for the potential value of our Phylomer libraries as a source of novel peptide drug candidates," Watt added.
Phylogica is entitled to an undisclosed milestone payment under the terms of the deal.